Each summer, the release of Clarivate’s annual Journal Citation Reports brings a moment of reflection and recognition across the academic publishing world. Impact factors, though only one of several metrics used to evaluate journal performance, remain a significant indicator of influence and visibility. This year, we are delighted to share that two of the British Society for Immunology’s journals, Clinical & Experimental Immunology (CEI) and Immunotherapy Advances (ITA) have seen notable increases in their impact factors, a reflection of their continued commitment to publishing timely, high-quality immunological research.
Impact factor milestones for CEI and ITA
We are proud to announce that Immunotherapy Advances, our open access journal dedicated to immunotherapy research, has achieved an impact factor of 4.9. This places ITA firmly in the first quartile of immunology journals, affirming its status as a leading voice in the field. Since its launch, ITA has established itself as a go-to platform for cutting-edge advances in immunotherapy, from cancer and autoimmune diseases to novel cellular and molecular interventions.
Meanwhile, Clinical & Experimental Immunology, a longstanding and respected cornerstone of the BSI journal portfolio, has reached an impact factor of 3.8, marking a significant increase from previous years. CEI now sits in the second quartile for immunology journals, underscoring its continued relevance and scholarly impact across the field. As a journal that spans both fundamental and translational immunology, CEI remains a trusted source for rigorous, impactful research.
These achievements are the result of outstanding leadership and community support. We extend our sincere thanks to Professor Tim Elliott, founding Editor-in-Chief of Immunotherapy Advances, and Professor Claudia Mauri, Editor-in-Chief of Clinical & Experimental Immunology. Their dedication, alongside the tireless work of their editorial teams, reviewers, authors and readers, has driven the continued success of these journals.
Discovery Immunology: building momentum
While Discovery Immunology (DSI), our newest journal, does not yet have an impact factor, it is making significant strides. The journal is now indexed in PubMed Central, a critical milestone that enhances visibility and accessibility. In 2024, DSI expanded its scope to include veterinary immunology, widening its reach and relevance across species and research disciplines. As DSI continues to attract high-quality submissions, we look forward to seeing its future metrics reflect the journal’s growth and impact.
Beyond impact factors: broader metrics of success
While we celebrate this year’s impact factors, we also recognise that they are just one piece of the puzzle. Journal performance is multifaceted, and other key metrics help illustrate the wider picture of reach, engagement and efficiency.
Clinical & Experimental Immunology
- Mean time to first decision: 21 days
- Mean time to final decision: 36 days
- 82,616 Altmetric mentions in the last year
- Yearly usage: 622,576 full-text downloads
- CiteScore 2024: 7.5
Immunotherapy Advances
- Mean time to first decision: 33 days
- Mean time to final decision: 72 days
- 7,890 Altmetric mentions in the last year
- Yearly usage: 61,176 full-text downloads
- CiteScore 2024: 8.3
- Indexed in the PubMed Central, Scopus and the Directory of Open Access Journals
Discovery Immunology
- Mean time to first decision: 36 days
- Mean time to final decision: 85 days
- 5,773 Altmetric mentions in the last year
- Yearly usage: 44,566 full-text downloads
- CiteScore 2024: 2.0
- Indexed in the Directory of Open Access Journals, Dimensions and Google Scholar
Looking ahead
The sustained growth of all three BSI journals is a testament to our vibrant immunology community and the shared commitment to advancing knowledge and improving health. These new metrics reinforce our collective goal: to publish rigorous, timely and impactful research that supports the immunology community and informs scientific progress.
As we reflect on this year’s successes, we also remain mindful of the broader context in which these metrics sit. While impact factors can open doors and signal visibility, it is the quality, relevance and integrity of our published work that truly define our journals. We are proud of the contributions made by our community and are excited for the continued development of Clinical & Experimental Immunology, Immunotherapy Advances, and Discovery Immunology in the years ahead.
We thank our editorial teams, reviewers, authors and readers for their unwavering support. Here’s to another year of excellence in immunological research.